CANCER DISCOVERY CONTENTS

MAY 2012 ▪ VOLUME 2 ▪ NUMBER 5







Downloaded from cancerdiscovery.aacrjournals.org on May 19, 2019. © 2012 American Association for Cancer Research.

For more News and Research Watch, visit *Cancer Discovery* online at http://CDnews.aacrjournals.org. Online-only News stories include the following:

- Annotated Cell-Line Resources Speed Discovery
- Phase II Trial for Lymphoma Gives Promising Early Results
- Targeted Combo Effective for Refractory Ewing Sarcoma
- Novel PI3K Inhibitors Enter Human Studies
- An EMPaCT on Minority Recruitment
- MEK Inhibition Aids in Serous Ovarian Cancer

ON THE COVER Vivanco and colleagues demonstrated that glioma-specific EGFR extracellular domain mutants were more sensitive to type II EGFR inhibitors (e.g., lapatinib) that stabilize an inactive kinase conformation than type I EGFR inhibitors (e.g., erlotinib) that target the active kinase conformation more commonly found in *EGFR*-mutant lung cancers. In a related article, Barkovich and colleagues found that the rapid release of erlotinib by glioma-specific EGFR mutants rendered them less sensitive to erlotinib than lung cancer–derived EGFR mutants. Together, these studies provide explanations for the limited success of first-generation EGFR inhibitors in treatment of *EGFR*-mutant gliomas and suggest alternative EGFR inhibition strategies may work best in these tumors. For details, please see the article by Vivanco and colleagues on page 458 and the article by Barkovich and colleagues on page 450.

Downloaded from cancerdiscovery.aacrjournals.org on May 19, 2019. © 2012 American Association for Cancer Research.

AACR American Association for Cancer Research

CANCER DISCOVERY

2 (5)

Cancer Discovery 2012;2:OF7-471.

Updated version	Access the most recent version of this article at: http://cancerdiscovery.aacrjournals.org/content/2/5

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/2/5. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.

Downloaded from cancerdiscovery.aacrjournals.org on May 19, 2019. © 2012 American Association for Cancer Research.